{"hands_on_practices": [{"introduction": "The production of diphtheria toxin by Corynebacterium diphtheriae is tightly controlled by the availability of iron, a classic example of environmental sensing regulating virulence. This exercise challenges you to translate this biological mechanism into a quantitative framework using a Hill-type model of gene repression [@problem_id:4623996]. By deriving the relationship between iron concentration and toxin gene expression, you will practice modeling fundamental biological processes and appreciate how such models can predict bacterial behavior under different conditions.", "problem": "Corynebacterium diphtheriae produces diphtheria toxin, and its transcription is repressed by the Diphtheria Toxin Repressor (DtxR) when iron is available. From the Central Dogma of molecular biology and equilibrium gene regulation, assume the following fundamental base: transcriptional output is proportional to the probability that the promoter is in its transcriptionally competent (unrepressed) state; DtxR becomes an active repressor upon binding iron; and the iron-dependent activation of DtxR can be captured by a Hill-type binding model rooted in mass-action equilibrium, with Hill coefficient $n$ and a characteristic concentration $K$ at which activation is half-maximal.\n\nStarting from these bases, derive the functional dependence of toxin messenger ribonucleic acid (mRNA) level on extracellular iron concentration $I$ and then compute the expected fold-change in toxin mRNA (defined as $E(I)/E_{\\max}$, where $E_{\\max}$ is the expression in iron starvation) for two iron concentrations. Use $n=2$, $K=0.2$ micromolar, $I_{\\text{low}}=0.05$ micromolar, and $I_{\\text{high}}=2.0$ micromolar. Report the two fold-changes in the order $\\left(I_{\\text{low}}, I_{\\text{high}}\\right)$.\n\nExpress your final numerical values as decimal fractions, and round your results to four significant figures. No units are required in the final numerical answers.", "solution": "The problem asks for the derivation of the functional dependence of diphtheria toxin mRNA levels on extracellular iron concentration, and for the calculation of the relative expression at two specific iron concentrations. The problem is scientifically sound and well-posed.\n\nThe derivation begins from the fundamental principles provided.\n1.  The level of toxin messenger ribonucleic acid (mRNA), denoted as $E$, is proportional to the probability that the gene's promoter is in a transcriptionally competent, or unrepressed, state. Let this probability be $P_{\\text{unrepressed}}$. We can write this relationship as:\n    $$E(I) = E_{\\max} \\cdot P_{\\text{unrepressed}}(I)$$\n    where $I$ is the extracellular iron concentration and $E_{\\max}$ is the proportionality constant representing the maximum possible expression level, which occurs when repression is completely absent (i.e., in complete iron starvation, $I \\to 0$).\n\n2.  The problem states that the Diphtheria Toxin Repressor (DtxR) becomes an active repressor upon binding iron. The overall effect of this iron-dependent repression is captured by a Hill-type model. This is a standard formalism in biophysics for describing a cooperative dose-response relationship. For a process of repression, the probability of the system being in the \"on\" or unrepressed state is described by an inverted Hill function of the repressing agent's concentration, which in this case is iron, $I$.\n\n3.  The inverted Hill function for $P_{\\text{unrepressed}}$ as a function of the concentration $I$ is given by:\n    $$P_{\\text{unrepressed}}(I) = \\frac{K^n}{K^n + I^n}$$\n    Here, $K$ is the characteristic concentration of iron at which the repressive effect is half-maximal (i.e., $E(K) = E_{\\max}/2$), and $n$ is the Hill coefficient, which quantifies the steepness or cooperativity of the repressive response.\n\n4.  Substituting this expression for $P_{\\text{unrepressed}}(I)$ back into our initial equation for the mRNA level $E(I)$, we obtain the derived functional dependence:\n    $$E(I) = E_{\\max} \\frac{K^n}{K^n + I^n}$$\n    This equation describes the level of toxin mRNA as a function of iron concentration $I$, based on the provided principles.\n\nNext, we must compute the expected fold-change in toxin mRNA, which is defined in the problem as $\\frac{E(I)}{E_{\\max}}$. Let us denote this fold-change as $F(I)$. Using the derived expression for $E(I)$:\n$$F(I) = \\frac{E(I)}{E_{\\max}} = \\frac{1}{E_{\\max}} \\left( E_{\\max} \\frac{K^n}{K^n + I^n} \\right) = \\frac{K^n}{K^n + I^n}$$\nThis is the general expression for the fold-change.\n\nWe are given the following parameter values:\n-   Hill coefficient: $n = 2$\n-   Characteristic concentration: $K = 0.2$ micromolar\n-   Low iron concentration: $I_{\\text{low}} = 0.05$ micromolar\n-   High iron concentration: $I_{\\text{high}} = 2.0$ micromolar\n\nWe now substitute these values into the fold-change equation $F(I) = \\frac{K^2}{K^2 + I^2}$ to find the required numerical answers.\n\nFor the low iron concentration, $I_{\\text{low}} = 0.05$:\n$$F(I_{\\text{low}}) = \\frac{(0.2)^2}{(0.2)^2 + (0.05)^2} = \\frac{0.04}{0.04 + 0.0025} = \\frac{0.04}{0.0425}$$\n$$F(I_{\\text{low}}) \\approx 0.94117647...$$\nRounding to four significant figures, we get $0.9412$.\n\nFor the high iron concentration, $I_{\\text{high}} = 2.0$:\n$$F(I_{\\text{high}}) = \\frac{(0.2)^2}{(0.2)^2 + (2.0)^2} = \\frac{0.04}{0.04 + 4.0} = \\frac{0.04}{4.04}$$\n$$F(I_{\\text{high}}) \\approx 0.00990099...$$\nRounding to four significant figures, we get $0.009901$.\n\nThe problem asks for the two fold-changes in the order of $(I_{\\text{low}}, I_{\\text{high}})$. The results are $(0.9412, 0.009901)$.", "answer": "$$\\boxed{\\begin{pmatrix} 0.9412 & 0.009901 \\end{pmatrix}}$$", "id": "4623996"}, {"introduction": "Moving from theoretical modeling to practical application, the next challenge lies in accurately detecting and quantifying toxigenicity in clinical isolates. This problem guides you through the design and validation of a quantitative reverse transcription-PCR (qRT-PCR) assay, a cornerstone of modern molecular diagnostics [@problem_id:4624054]. You will not only consider the critical technical controls for a robust assay but also apply statistical reasoning to define a diagnostic threshold, bridging the gap between raw molecular data and clinically relevant interpretation.", "problem": "A clinical laboratory seeks to develop a quantitative reverse transcription–polymerase chain reaction (qRT–PCR) assay to quantify expression of the diphtheria toxin gene ($tox$) in Corynebacterium diphtheriae and to define a cycle threshold ($C_T$)–based decision rule that correlates with the Elek immunodiffusion test for toxin production. The biological and measurement bases are as follows.\n\n- The Central Dogma of Molecular Biology states that DNA is transcribed to messenger ribonucleic acid (mRNA), which is translated to protein. Diphtheria toxin protein abundance measured by the Elek test arises from $tox$ mRNA processed through translation.\n- In polymerase chain reaction (PCR), with near–perfect efficiency, each cycle approximately doubles the amplicon quantity; thus, under ideal conditions, the starting copy number is inversely proportional to $2^{C_T}$, and a difference of one cycle corresponds to a factor of $2$ in starting template abundance.\n- qRT–PCR quantifies mRNA by reverse transcription to complementary DNA (cDNA), followed by PCR amplification and fluorescence detection. The cycle threshold $C_T$ is defined as the cycle number at which fluorescence crosses a fixed detection threshold.\n- To control for sample–to–sample variation, normalization to a stably expressed housekeeping mRNA (for example, the RNA polymerase beta subunit gene, $rpoB$) is standard. Let $\\Delta C_T = C_T(\\mathrm{tox}) - C_T(\\mathrm{rpoB})$; by the doubling law, the relative abundance of $tox$ mRNA to $rpoB$ mRNA is $R = 2^{-\\Delta C_T}$.\n\nYou perform pilot measurements under iron–limited growth to induce $tox$ transcription (consistent with Diphtheria toxin repressor regulation) on isolates already characterized by Elek testing. The empirical distributions of $\\Delta C_T$ appear approximately Gaussian within each Elek class, with equal variances, and are summarized as:\n- Elek–positive isolates: mean $\\mu_{+} = -4.0$ cycles, standard deviation $\\sigma = 1.5$ cycles.\n- Elek–negative isolates: mean $\\mu_{-} = 1.0$ cycles, standard deviation $\\sigma = 1.5$ cycles.\n\nAssume equal prior probabilities of Elek positivity and negativity and equal misclassification costs. The amplification efficiency for both primer sets is verified with a standard curve to be approximately $E \\approx 2.0$–fold per cycle over the dynamic range, and melt–curve analysis confirms a single specific amplicon without primer–dimer artifacts.\n\nWhich single option correctly specifies both (i) essential assay design elements needed to validly quantify $tox$ mRNA and avoid genomic deoxyribonucleic acid (DNA) confounding, and (ii) a data–driven $\\Delta C_T$–based classification threshold that maximizes balanced accuracy (equivalently, Youden’s $J$) under the stated distributional assumptions, thereby best correlating with Elek test positivity?\n\nA. Treat RNA with deoxyribonuclease, include a no–reverse–transcriptase control and a no–template control, design primers within the $tox$ coding region avoiding repetitive sequences, normalize to $rpoB$, verify per–assay efficiency $E$ within $[1.9, 2.1]$, and call an isolate Elek–correlated positive if $\\Delta C_T \\le -1.5$ cycles.\n\nB. Skip deoxyribonuclease treatment, use $16\\mathrm{S}$ ribosomal ribonucleic acid (rRNA) as the reference, accept any melt profile with multiple peaks, and call positive if the fold ratio $R = 2^{-\\Delta C_T} \\ge 2.0$ (equivalently, $\\Delta C_T \\le -1.0$).\n\nC. Use the comparative $\\Delta \\Delta C_T$ method with a calibrator strain that lacks the $tox$ gene, normalize to $rpoB$, and call positive if $R \\ge 16.0$ (equivalently, $\\Delta \\Delta C_T \\le -4.0$).\n\nD. Use only absolute $C_T$ for $tox$ without normalization, omit no–reverse–transcriptase and deoxyribonuclease controls, and call positive if $C_T(\\mathrm{tox}) \\le 35$ cycles.\n\nE. Treat RNA with deoxyribonuclease and include a no–template control, normalize to $rpoB$, but call positive if $\\Delta C_T \\le -3.0$ cycles to be conservative.\n\nSelect the single best option.", "solution": "The user has requested a rigorous validation of a problem concerning a quantitative reverse transcription–polymerase chain reaction (qRT–PCR) assay, followed by a detailed solution.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n-   **Assay Goal:** Develop a qRT-PCR assay to quantify the expression of the diphtheria toxin gene ($tox$) and establish a decision rule based on the cycle threshold ($C_T$) that correlates with the Elek immunodiffusion test for toxin production.\n-   **Biological/Measurement Principles:**\n    1.  Central Dogma: DNA $\\rightarrow$ mRNA $\\rightarrow$ Protein. Elek test measures protein; qRT-PCR measures mRNA.\n    2.  PCR amplification: Amplicon quantity approximately doubles each cycle, so starting copy number is inversely proportional to $2^{C_T}$.\n    3.  qRT-PCR measures mRNA via reverse transcription to cDNA followed by PCR. $C_T$ is the cycle number at which fluorescence crosses a fixed threshold.\n    4.  Normalization is performed using a housekeeping gene, RNA polymerase beta subunit ($rpoB$).\n    5.  Relative quantification formula: $\\Delta C_T = C_T(\\mathrm{tox}) - C_T(\\mathrm{rpoB})$.\n    6.  Relative abundance formula: $R = 2^{-\\Delta C_T}$.\n-   **Pilot Study Data and Conditions:**\n    1.  Growth condition: Iron-limited to induce $tox$ transcription.\n    2.  Empirical distributions of $\\Delta C_T$ are approximately Gaussian with equal variances.\n    3.  For Elek-positive isolates: mean $\\mu_{+} = -4.0$ cycles, standard deviation $\\sigma = 1.5$ cycles.\n    4.  For Elek-negative isolates: mean $\\mu_{-} = 1.0$ cycles, standard deviation $\\sigma = 1.5$ cycles.\n-   **Assumptions and Verifications:**\n    1.  Equal prior probabilities of Elek-positive and Elek-negative classes.\n    2.  Equal misclassification costs.\n    3.  Amplification efficiency for both primer sets, $E \\approx 2.0$-fold per cycle.\n    4.  Melt-curve analysis confirms a single specific amplicon.\n-   **Question:** The user seeks the single option that correctly specifies both (i) essential assay design elements to validly quantify $tox$ mRNA while avoiding genomic DNA confounding, and (ii) a data-driven $\\Delta C_T$-based classification threshold that maximizes balanced accuracy (or Youden’s $J$) under the stated assumptions.\n\n**Step 2: Validate Using Extracted Givens**\n\n1.  **Scientifically Grounded:** The problem is firmly based on established principles of molecular biology (Central Dogma, gene expression), molecular diagnostics (qRT-PCR, normalization, amplification efficiency), and biostatistics (Gaussian distribution modeling, classification theory). The regulation of the $tox$ gene by iron availability via the DtxR repressor is a well-known mechanism in *Corynebacterium diphtheriae*. The description of qRT-PCR methodology and data analysis ($\\Delta C_T$, $2^{-\\Delta C_T}$ method) is accurate and standard. All premises are scientifically sound.\n2.  **Well-Posed:** The problem is well-posed. It asks for two components: correct experimental design for a qRT-PCR assay and the derivation of an optimal statistical decision boundary. The statistical part is a classic binary classification problem with fully specified probability distributions and an explicit optimization criterion (maximize balanced accuracy). This problem has a unique, definite solution. The experimental design part relies on established best practices (e.g., MIQE guidelines), which are objective standards in the field.\n3.  **Objective:** The language is technical, precise, and free of subjective or ambiguous terminology. All assumptions are explicitly stated.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is scientifically sound, well-posed, objective, and self-contained. It is **valid**. The solution process will now proceed.\n\n### Solution Derivation\n\nThe problem requires identifying the option that correctly addresses two independent criteria: (i) proper qRT-PCR assay design and (ii) the optimal classification threshold for $\\Delta C_T$.\n\n**Part (i): Essential Assay Design Elements**\n\nA valid qRT-PCR assay for quantifying mRNA expression, especially from a bacterial source (which lacks introns), must include specific controls to ensure the signal originates from mRNA and not from contaminating genomic DNA (gDNA).\n\n1.  **Handling gDNA Contamination:** Since bacterial genes lack introns, primers designed for a coding sequence like $tox$ will amplify both cDNA (derived from mRNA) and any contaminating gDNA. Therefore, gDNA must be removed from the RNA preparation. This is achieved by treating the RNA sample with **deoxyribonuclease (DNase)**.\n2.  **Verifying gDNA Removal:** To confirm the effectiveness of the DNase treatment and the absence of a signal from gDNA, a **no-reverse-transcriptase (-RT or NRT) control** is essential. This control reaction contains the RNA sample and all PCR reagents except for the reverse transcriptase enzyme. No cDNA is synthesized. Any amplification detected in this control must be from contaminating gDNA. An assay is valid only if this control is negative (i.e., shows no amplification or a very high $C_T$ value).\n3.  **Contamination Control:** A **no-template control (NTC)**, which contains all reaction components but no nucleic acid template, must be included to detect reagent contamination or primer-dimer formation.\n4.  **Normalization:** As stated in the problem, sample-to-sample variations in RNA quantity and quality, and reverse transcription efficiency, must be corrected. This is done by normalizing the target gene ($tox$) expression to that of a stably expressed **housekeeping gene**. The problem suggests $rpoB$, which is a standard choice. Using absolute $C_T$ values is not robust.\n5.  **Amplification Efficiency:** The relative quantification formula $R = 2^{-\\Delta C_T}$ is predicated on the assumption that the PCR amplification efficiency ($E$) for both the target and reference gene is $2.0$ (i.e., $100\\%$). It is a critical quality control step to experimentally verify that the efficiency is close to this value (e.g., $E \\in [1.9, 2.1]$) for both primer sets.\n6.  **Specificity:** Melt-curve analysis is used to verify that only a single, specific product is amplified, as confirmed in the problem statement. Multiple melt peaks would indicate non-specific products or primer-dimers, invalidating the results.\n\nA correct assay design will incorporate all these elements: DNase treatment, -RT control, NTC, normalization to a suitable reference gene, and verification of efficiency.\n\n**Part (ii): Optimal $\\Delta C_T$ Classification Threshold**\n\nThe goal is to find the threshold $c$ for $\\Delta C_T$ that maximizes balanced accuracy, which is equivalent to maximizing Youden's $J$ statistic ($J = \\text{sensitivity} + \\text{specificity} - 1$). The decision rule is: classify as positive if $\\Delta C_T \\le c$.\n\nWe are given two Gaussian distributions for $\\Delta C_T$:\n-   Elek-positive ($P$): $\\mathcal{N}(\\mu_{+}, \\sigma^2)$ where $\\mu_{+} = -4.0$ and $\\sigma = 1.5$.\n-   Elek-negative ($N$): $\\mathcal{N}(\\mu_{-}, \\sigma^2)$ where $\\mu_{-} = 1.0$ and $\\sigma = 1.5$.\n\nThe problem states equal prior probabilities and equal misclassification costs. For two Gaussian distributions with equal variances, the threshold that minimizes the total probability of error (and maximizes balanced accuracy under these conditions) is the point where their probability density functions are equal. This point is simply the midpoint of their means.\n\nThe optimal threshold $c$ is calculated as:\n$$ c = \\frac{\\mu_{+} + \\mu_{-}}{2} $$\nSubstituting the given values:\n$$ c = \\frac{(-4.0) + (1.0)}{2} = \\frac{-3.0}{2} = -1.5 $$\n\nTherefore, the data-driven classification rule that maximizes balanced accuracy is to call an isolate positive if its measured $\\Delta C_T \\le -1.5$ cycles.\n\n### Option-by-Option Analysis\n\n**A. Treat RNA with deoxyribonuclease, include a no–reverse–transcriptase control and a no–template control, design primers within the $tox$ coding region avoiding repetitive sequences, normalize to $rpoB$, verify per–assay efficiency $E$ within $[1.9, 2.1]$, and call an isolate Elek–correlated positive if $\\Delta C_T \\le -1.5$ cycles.**\n\n-   **Assay Design:** This option correctly lists all the essential components of a robust qRT-PCR assay: DNase treatment, -RT control, NTC, appropriate normalization ($rpoB$), and efficiency verification. This methodology is rigorous and scientifically sound.\n-   **Threshold:** The proposed threshold is $\\Delta C_T \\le -1.5$ cycles, which matches our calculated optimal threshold for maximizing balanced accuracy.\n\n-   **Verdict:** **Correct**. This option is correct on both the experimental design and the statistical analysis.\n\n**B. Skip deoxyribonuclease treatment, use $16\\mathrm{S}$ ribosomal ribonucleic acid (rRNA) as the reference, accept any melt profile with multiple peaks, and call positive if the fold ratio $R = 2^{-\\Delta C_T} \\ge 2.0$ (equivalently, $\\Delta C_T \\le -1.0$).**\n\n-   **Assay Design:** This describes a deeply flawed assay. Skipping DNase treatment invites false positives from gDNA. Using $16\\mathrm{S}$ rRNA is suboptimal for normalizing mRNA due to its vast abundance and different biogenesis. Accepting multiple melt peaks violates the principle of assay specificity.\n-   **Threshold:** The threshold $\\Delta C_T \\le -1.0$ is not the optimal threshold of $-1.5$.\n\n-   **Verdict:** **Incorrect**. Both the assay design and the threshold are incorrect.\n\n**C. Use the comparative $\\Delta \\Delta C_T$ method with a calibrator strain that lacks the $tox$ gene, normalize to $rpoB$, and call positive if $R \\ge 16.0$ (equivalently, $\\Delta \\Delta C_T \\le -4.0$).**\n\n-   **Assay Design:** The $\\Delta \\Delta C_T$ method is inappropriate for this classification task. It is used to compare relative expression levels between samples (e.g., treated vs. control), not to classify a single sample based on an absolute criterion. A strain lacking the target gene is a negative control, not a calibrator.\n-   **Threshold:** A threshold of $\\Delta C_T \\le -4.0$ (since $R = 2^{-\\Delta C_T} \\ge 16 = 2^4$) is the mean of the positive distribution, which would yield a sensitivity of only $50\\%$ and is therefore not optimal. The use of $\\Delta \\Delta C_T$ is also conceptually incorrect.\n\n-   **Verdict:** **Incorrect**. The analytical method is inappropriate, and the threshold is suboptimal.\n\n**D. Use only absolute $C_T$ for $tox$ without normalization, omit no–reverse–transcriptase and deoxyribonuclease controls, and call positive if $C_T(\\mathrm{tox}) \\le 35$ cycles.**\n\n-   **Assay Design:** This approach is fundamentally flawed. The omission of normalization and critical controls (-RT, DNase) makes the results unreliable and uninterpretable. An absolute $C_T$ value is highly susceptible to variations in sample input and reaction efficiencies.\n-   **Threshold:** The threshold $C_T(\\mathrm{tox}) \\le 35$ is arbitrary and not derived from the $\\Delta C_T$ distributions provided in the problem.\n\n-   **Verdict:** **Incorrect**. The assay design is invalid, and the threshold is arbitrary.\n\n**E. Treat RNA with deoxyribonuclease and include a no–template control, normalize to $rpoB$, but call positive if $\\Delta C_T \\le -3.0$ cycles to be conservative.**\n\n-   **Assay Design:** This design is an improvement over B, C, and D, but it is incomplete. It critically omits the **no-reverse-transcriptase (-RT) control**, which is necessary to confirm that the signal is from mRNA and not residual gDNA, even after DNase treatment.\n-   **Threshold:** The threshold $\\Delta C_T \\le -3.0$ is not the value of $-1.5$ that was calculated to maximize balanced accuracy. While being more specific (fewer false positives) at the cost of lower sensitivity, it does not meet the specified optimization criterion.\n\n-   **Verdict:** **Incorrect**. The assay design is incomplete, and the threshold is suboptimal for the stated goal.\n\nBased on the detailed analysis, Option A is the only one that presents both a methodologically sound assay design and the correctly calculated optimal decision threshold.", "answer": "$$\\boxed{A}$$", "id": "4624054"}, {"introduction": "The ultimate goal of understanding diphtheria is to control its spread within populations, primarily through vaccination. This exercise shifts our focus from the molecular and diagnostic scale to the epidemiological scale, introducing the concept of the effective reproduction number ($R_e$) [@problem_id:4635586]. By calculating how vaccination coverage and effectiveness reduce the potential for transmission, you will gain a quantitative understanding of herd immunity and the principles that underpin public health strategies for preventing outbreaks of vaccine-preventable diseases.", "problem": "A respiratory outbreak of diphtheria caused by Corynebacterium diphtheriae is being assessed in a district with ongoing routine immunization using diphtheria toxoid–containing vaccines. Consider a homogeneous, well-mixed population in the Susceptible–Infectious–Removed (SIR) framework where the basic reproduction number $R_0$ is defined as the expected number of secondary infections produced by a single typical infectious case in a fully susceptible population. The effective reproduction number $R_e$ is defined as the expected number of secondary infections in the current population with an imperfectly susceptible fraction.\n\nAssume that vaccination coverage is $v$ and vaccine effectiveness against infection is $E$, interpreted as the probability that a vaccinated individual is immune to infection upon exposure. Assume that:\n- Vaccination status is independent of exposure and infectiousness.\n- Those vaccinated have sterilizing immunity with probability $E$ and otherwise are fully susceptible.\n- The unvaccinated are fully susceptible.\n- Pre-existing natural immunity from prior infection is negligible.\n\nGiven $R_0 = 3.2$, $v = 0.65$, and $E = 0.90$, derive from first principles the expression for $R_e$ under these assumptions and compute its value. Provide only the numerical value of $R_e$ rounded to four significant figures. No units are required.", "solution": "The problem is valid. It is a well-posed problem in mathematical epidemiology that is scientifically grounded, self-contained, and free of contradictions. I will now proceed with the solution.\n\nThe problem asks for the derivation and calculation of the effective reproduction number, $R_e$, in a population with partial vaccine coverage and imperfect vaccine effectiveness. We begin from first principles, as requested.\n\nThe basic reproduction number, $R_0$, is defined as the average number of secondary cases produced by a single infectious individual in a completely susceptible population. The effective reproduction number, $R_e$, modifies this value to account for the actual proportion of susceptible individuals in the population at a given time. The fundamental relationship between $R_e$ and $R_0$ is:\n$$\nR_e = R_0 \\times s\n$$\nwhere $s$ is the fraction of the population that is susceptible to the infection.\n\nOur task is to determine the susceptible fraction $s$ based on the given parameters: vaccination coverage $v$ and vaccine effectiveness $E$. The population can be partitioned into two groups: those who are vaccinated (a fraction $v$ of the population) and those who are unvaccinated (a fraction $1-v$).\n\nAccording to the problem statement, we assume:\n1.  Unvaccinated individuals are fully susceptible. The contribution of this group to the total susceptible fraction is $1 \\times (1-v) = 1-v$.\n2.  Vaccinated individuals (fraction $v$) have a probability $E$ of being fully immune (sterilizing immunity) and a probability $(1-E)$ of remaining fully susceptible. Therefore, the fraction of the total population that is vaccinated but remains susceptible is $v \\times (1-E)$.\n\nThe total susceptible fraction, $s$, is the sum of the susceptible individuals from both the unvaccinated and vaccinated groups.\n$$\ns = (\\text{fraction unvaccinated and susceptible}) + (\\text{fraction vaccinated and susceptible})\n$$\n$$\ns = (1-v) + v(1-E)\n$$\nWe can simplify this expression for $s$:\n$$\ns = 1 - v + v - vE = 1 - vE\n$$\nThis expression, $s = 1 - vE$, represents the fraction of the population that is not effectively protected by the vaccination program. The term $vE$ represents the proportion of the total population that is immune due to vaccination.\n\nNow, we substitute this expression for $s$ back into the equation for $R_e$:\n$$\nR_e = R_0 (1 - vE)\n$$\nThis is the derived expression for the effective reproduction number under the stated assumptions.\n\nThe problem provides the following numerical values:\n- Basic reproduction number, $R_0 = 3.2$\n- Vaccination coverage, $v = 0.65$\n- Vaccine effectiveness, $E = 0.90$\n\nWe substitute these values into the derived equation to compute the value of $R_e$:\n$$\nR_e = 3.2 \\times (1 - (0.65 \\times 0.90))\n$$\nFirst, calculate the product inside the parenthesis:\n$$\n0.65 \\times 0.90 = 0.585\n$$\nThis value, $0.585$, represents the fraction of the total population that is immune due to vaccination.\nNext, we calculate the term $(1 - vE)$, which is the susceptible fraction $s$:\n$$\ns = 1 - 0.585 = 0.415\n$$\nThis means that $41.5\\%$ of the population remains susceptible to the infection.\nFinally, we calculate $R_e$:\n$$\nR_e = 3.2 \\times 0.415\n$$\n$$\nR_e = 1.328\n$$\nThe calculated value is $1.328$. The problem requires the answer to be rounded to four significant figures. Since our result already has exactly four significant figures, no further rounding is needed. The effective reproduction number is $1.328$. This value being greater than $1$ suggests that, despite the vaccination campaign, the disease can still spread and cause an epidemic in the population.", "answer": "$$\\boxed{1.328}$$", "id": "4635586"}]}